Dual targeting of EphA2 and FAK in ovarian carcinoma

Abstract

EphA2 gene silencing has been shown to result in anti-tumor efficacy. Here we

considered whether silencing additional targets downstream of EphA2 would further

enhance the therapeutic effect. EphA2 targeted siRNA was tested in combination with

either FAK or Src targeted siRNA using DOPC nanoliposomes in orthotopic models of

ovarian carcinoma. The effects of therapy were determined by changes in tumor weight,

proliferation (Ki-67), and microvessel density (CD31). In our initial in vivo study, EphA2

plus FAK silencing resulted in the greatest reduction in tumor growth (by 73%, P